XML 37 R19.htm IDEA: XBRL DOCUMENT
v3.19.2

Note 12 - Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2019
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. Segment Information: The Company has two reportable segments based on the nature of its products; they are Protein Sciences and Diagnostics and Genomics. The Company's Protein Sciences segment is comprised of the Reagent Sol utions and the Analytical Solutions operating segment. These businesses manufacture consumables used for conducting laboratory experiments by both industry and academic scientists within the biotechnology and biomedical life science fields. No customer in the Protein Sciences segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2019 , 2018, and 2017. The Company's Diagnostics and Genomics is comprised of the Diagnostics, Genomics, and Exosome operating segments. The Diagnostics division consists of the Diagnostics operating segment and develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits, and the Genomics division consists of the Genomics and Exosome operating segments and sells a portfolio of clinical molecular diagnostic oncology assays, as well as tissue-based in-situ hybridization assays for research in clinical use. No customer in the Diagnostics and Genomics segment accounted for more than 10% of the segment’s net sales for the fiscal years ended June 30, 2019, 2018, and 2017. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands):
|  | Year Ended June 30, |
|  | 201 9 |  |  | 201 8 |  |  | 201 7 |
Net sales: |  |  |  |  |  |  |  |  |  |  |  |
Protein Sciences |  | $ | 543,159 |  |  | $ | 482,378 |  |  | $ | 419,365 |
Diagnostics and Genomics |  |  | 171,674 |  |  |  | 161,151 |  |  |  | 143,742 |
Intersegment |  |  | (827 | ) |  |  | (536 | ) |  |  | (104 | )
Consolidated net sales |  | $ | 714,006 |  |  | $ | 642,993 |  |  | $ | 563,003 |
Operating Income: |  |  |  |  |  |  |  |  |  |  |  |
Protein Sciences |  | $ | 240,919 |  |  | $ | 209,880 |  |  | $ | 184,095 |
Diagnostics and Genomics |  |  | 10,079 |  |  |  | 35,496 |  |  |  | 29,291 |
Segment operating income |  |  | 250,998 |  |  |  | 245,376 |  |  |  | 213,386 |
Costs recognized upon sale of acquired inventory |  |  | (3,739 | ) |  |  | (2,455 | ) |  |  | (3,037 | )
Amortization of intangibles |  |  | (58,550 | ) |  |  | (46,983 | ) |  |  | (44,393 | )
Acquisition related expenses |  |  | (2,282 | ) |  |  | (24,429 | ) |  |  | (25,789 | )
Restructuring costs |  |  | - |  |  |  | (376 | ) |  |  | - |
Stock-based compensation |  |  | (33,057 | ) |  |  | (28,240 | ) |  |  | (14,631 | )
Corporate general, selling and administrative expenses |  |  | (6,651 | ) |  |  | (6,715 | ) |  |  | (4,952 | )
Consolidated operating income |  | $ | 146,719 |  |  | $ | 136,178 |  |  | $ | 120,584 |
The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by reportable segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each reportable segment’s operating results, it is not discretely identifiable. The Company has disclosed sales by geographic area based on the location of the customer or distributor in Note 2. The Company has disclosed d issagregated product and service revenue by consumables, instruments, and services in Note 2. The Company considers total instrument and total service revenue to represent similar groups of products in the fiscal years presented. The Company considered our consumables sold in the Protein Sciences and Diagnostics and Genomics segments to represent different groups of products and therefore have separately disclosed the related consumables revenue (in thousands) :
|  | Year Ended June 30, |
|  | 201 9 |  |  | 201 8 |  |  | 201 7 |
Consumables revenue - Protein Sciences |  | $ | 430,655 |  |  | $ | 384,350 |  |  | $ | 341,611 |
Consumables revenue - Diagnostics and Genomics |  |  | 158,324 |  |  |  | 150,388 |  |  |  | 134,930 |
Total consumable revenue |  | $ | 588,979 |  |  | $ | 534,738 |  |  | $ | 476,541 |
The following is financial information relating to geographic areas (in thousands):
|  | Year ended June 30, |
Long-lived assets: |  | 201 9 |  |  | 201 8 |
United States and Canada |  | $ | 138,016 |  |  | $ | 129,360 |
Europe |  |  | 14,439 |  |  |  | 14,597 |
Asia |  |  | 1,584 |  |  |  | 1,391 |
Total long-lived assets |  | $ | 154,039 |  |  | $ | 145,348 |
Intangible assets: |  |  |  |  |  |  |  |
United States and Canada |  | $ | 556,951 |  |  | $ | 417,430 |
Europe |  |  | 16,637 |  |  |  | 21,386 |
Asia |  |  | 5,841 |  |  |  | 7,516 |
Total intangible assets |  | $ | 579,429 |  |  | $ | 446,332 |
Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration